Two well-known pharmaceutical companies were acquired

Guide: How to expand the product line, how to select varieties through mergers and acquisitions, Guizhou Sanli Pharmaceutical's choice may be worth learning from.
with the vigorous implementation of health insurance control fees, hospital procurement mechanism will also change, which becomes a heavy reliance on a single variety of pharmaceutical companies worry - how to expand the product line in the future, how to choose varieties through mergers and acquisitions, Guizhou Sanli Pharmaceutical's choice may be worth learning from.
1, two pharmaceutical companies, was acquired recently, Guizhou Sanli Pharmaceuticals (hereinafter referred to as "Sanli Pharmaceuticals") issued a notice, intended to cash to Guizhou Hanfang Pharmaceutical Co., Ltd. (hereinafter referred to as "Hanfang Pharmaceutical"), Guiyang Dechangxiang Pharmaceutical Co., Ltd. (hereinafter referred to as "Dechangxiang Pharmaceuticals") increase dissonment, hanfang Pharmaceuticals, Dechangxiang Pharmaceuticals no more than 51% of the equity.
it is understood that Sanli Pharmaceuticals intends to pay a deposit of RMB 100 million to the asset control party, according to the agreement between the two parties, in addition to a deal price can not be agreed between the two sides, such as the company's unilateral reasons to terminate the transaction, the asset control party has the right not to refund the transaction deposit paid by the listed company.
According to preliminary estimates, this transaction may constitute a major asset reorganization as stipulated in the Measures for the Administration of Major Asset Reorganization of Listed Companies, and the Company will, in accordance with the relevant provisions of the listed stock exchange, employ independent financial advisers, legal advisers, audit institutions and evaluation institutions as soon as possible to carry out relevant intermediary structures.
the formal agreement signed by the parties to the transaction, the Company will submit matters related to the reorganization of major assets to the Board of Directors and the General Meeting of Shareholders for consideration in accordance with relevant laws, regulations and articles of association.
Guizhou Hanfang Pharmaceuticals official website shows that the company by the Hanfang Group to integrate its advantages of the Resources of Chinese medicine enterprises, with tablets, capsules, granules, syrups, lotions, combined agents, aerosols, agent 8 dosage forms, 81 approval numbers, of which 20 exclusive varieties, 6 patented varieties, 8 exclusive miao drugs, including gynecological re-creation capsules, jisuan sipha, jaundice and other key products.
, the key products of the gel-raised white capsules were included in the national major special, is an anti-tumor drug.
and Guizhou Dechangxiang Pharmaceutical Co. , Ltd. was founded in 1900 Guiyang "Dechangxiang medicine number", is China's top ten traditional Chinese medicine, founded in 1900, and Tongren Tang, Hu Qing Yutang and other side-by-side national well-known drug number, there is "hundreds of de Changxiang" name, it is understood that Guizhou Dechangxiang pharmaceutical tablets, capsules, granulated agents 11 GMP production lines, such as pills, dispersants, combinants, syrups, aerosols (foams), liquors, antimony agents, frying creams, (including Chinese medicine extraction) and other 11 GMP production lines;
, gynecological re-creation pills for the company's fist products, best-selling 70 years.
this time, Guizhou Sanli Pharmaceuticals intends to acquire 51% of Hanfang Pharmaceuticals and Dechangxiang Pharmaceuticals, or through the acquisition, to take the han fang Pharmaceutical and Dechangxiang Pharmaceuticals high-quality products, enrich the company's product line.
2, the listing of new shares, over-reliance on a single variety just in this year's April 28, Guizhou Sanli Pharmaceuticallanding on the Shanghai Stock Exchange. before
, as a leading domestic children's drug segment, Sanli Pharmaceuticals is the star company of the new three boards, widely sought after by investors, the market value once approached 4.5 billion yuan.
data show that the company's product varieties mainly around pediatrics, respiratory medicine, cardiovascular, digestive medicine and other fields, the main products for the open throat sword spray (children's type), open throat sword spray and strong tindo du Zhong capsules.
company's fist products open throat sword spray (child type) and open throat sword spray is a national patented productand exclusive varieties, has been included in the national health insurance catalog and some provinces of the local basic drugs catalog, clinically used for upper respiratory tract infections, acute and chronic pharyngitis, tonsillitis, sore throat, stomatitis, oral ulcers, gum swollen pain and other conditions.
it is known that the open throat sword spray (including children type) in China's children's throat diseases in the pharmaceutical market occupies a larger advantage, its throat diseasein in the drug spray market ranking also catch up with Guilin watermelon cream spray occupies the lead.
the prospectus of Guizhou Sanli Pharmaceuticals, sales revenue of this variety of children's products reached 275 million yuan, 407 million yuan, 518 million yuan and 241 million yuan, respectively, while adult product sales revenue was 53.96 million yuan, 81.62 million yuan, 93.18 million yuan and 45.55 million yuan, respectively.
together accounted for more than 95% of the company's main business revenue, contributing greatly to the company's performance.
to some extent, the extreme dependence on a single variety also brings hidden dangers to enterprises.
Guizhou Sanli Pharmaceuticals' 2020 half-year results forecast shows that the net profit attributable to shareholders of listed companies is expected to be 42 million yuan - 47 million yuan, down 14.67 percent to 23.75 percent year-on-year.
, the company said, in the first half of this year by the outbreak of the new crown in various places, the national residents of home isolation and self-protection awareness increased, the crowd gathering plummeted.
the previous year January-May for influenza, hand, foot and mouth disease and respiratory infectious diseases high incidence period, and this year due to the provinces, primary schools delayed the opening of the school, all kinds of workers, commercial delays to resume work, such as the population gathering decreased, the number of patients decreased relative to previous years.
the company's main products open throat sword spray (including children type) demand decreased from the same period last year, resulting in the company's main business revenue decline.
3, new product mergers and acquisitions, has begun to drug companies, a single variety of abnormally high proportion is a double-edged sword: on the one hand, the continued release of the variety can quickly promote the company's performance growth;
facing the company's product line single problem, Guizhou Sanli Pharmaceutical sanli pharmaceutical has previously been through the merger and acquisition action to deal with: March 1, 2018, Guizhou Sanli Pharmaceutical Co., Ltd. proposed to be assigned to Guizhou Green Sun Pharmaceutical Co., Ltd., for a price of 45.9 million yuan.
it is understood that Green Sun Pharmaceutical shas sourcing comprehensive production capacity of pharmaceuticals, health care products, health drinks and cosmetics, and is a high-tech production enterprise in Guizhou Province.
company has a Chinese medicine ointment preparation production line, capsule preparation production line and other health care products production line.
, the company produces a total of three ethnic drugs and 20 health care products products have been sold in 23 provinces and cities in the country, some products are also exported to Canada, the Netherlands, Hong Kong, Russia, Vietnam and other places.
from this point of view, Green Sun Pharmaceutical's five national exclusive Miao drug OTC products, can supplement the three-way pharmaceutical product group.
as a company to operate traditional Chinese medicine-based companies, Sanli Pharmaceuticals to buy Hanfang Pharmaceuticals and Dechangxiang Pharmaceuticals motivation, but also look at the other side of the Chinese medicine product reserves, to alleviate their excessive reliance on a single variety of disadvantage.
with the vigorous implementation of medical insurance control fees, hospital procurement mechanism will also change, which becomes a heavy reliance on a single variety of pharmaceutical companies worry - how to expand the product line in the future, how to select varieties through mergers and acquisitions, Guizhou Sanli Pharmaceutical sanli pharmaceutical choice may be worth learning from.
.